Key Highlights
- Q4 CARVYKTI net trade sales achieved $555M, representing 66% year-over-year growth across all markets.
- U.S. market generated $420M while overseas territories delivered $135M, tripling prior-year performance.
- Production infrastructure scaled to support 20,000 annual doses with 97–99% manufacturing success metrics.
- Patient data demonstrates 50.4-month median progression-free survival in critical treatment populations.
- Company forecasts achieving enterprise-level profitability throughout 2026.
Legend Biotech (LEGN) stock declined 1.77% to close at $18.80 despite maintaining robust commercial traction for CARVYKTI globally. Fourth-quarter net trade sales for the therapy reached $555 million, marking a 66% increase compared to the same period last year. With CARVYKTI achieving product-level profitability in 2025, the organization anticipates company-wide positive earnings by 2026, reinforcing confidence in Bio Legend stock’s future trajectory.
Legend Biotech Corporation, LEGN
Revenue Performance and Geographic Reach
CARVYKTI delivered $420 million in U.S. net trade sales during the quarter, climbing 38% year-over-year and expanding 6% from the previous quarter. Revenue from international territories totaled $135 million, exceeding triple the prior-year figure, with strong contributions from Germany, Spain, and Belgium. Bio Legend stock gains momentum from active operations across 14 global markets and availability at 294 authorized treatment centers worldwide.
The organization has established production infrastructure capable of manufacturing 10,000 doses annually and is collaborating with Johnson & Johnson to double that capacity to 20,000 units. Manufacturing quality metrics demonstrate exceptional consistency, with success rates between 97% and 99%, securing dependable supply chains for international distribution. These operational achievements underpin growing demand and bolster the investment case for Bio Legend stock.
Physicians increasingly administer CARVYKTI earlier in treatment sequences, with 65% of current patients receiving the therapy between second and fourth treatment lines. In Spain specifically, adoption rates for early-line administration reach 70% to 75%, mirroring emerging patterns across international markets. This shift toward earlier intervention could enhance patient outcomes while accelerating CARVYKTI revenue momentum.
Scientific Evidence and Treatment Protocol Advances
Extended follow-up from the CARTITUDE-1 and CARTITUDE-4 clinical programs revealed median progression-free survival of 50.4 months among triple-class-exposed multiple myeloma patients. Standard-risk cohorts maintained 80% progression-free status at 2.5 years, with 93% survival rates among those remaining progression-free after twelve months. These findings validate CARVYKTI’s long-term efficacy and strengthen the scientific foundation supporting Bio Legend stock.
Current patient management protocols prioritize bridging therapies designed to decrease tumor burden before CAR T-cell infusion and minimize neurotoxicity risks. Clinical observations confirm zero incidence of colitis or Parkinsonism among patients receiving appropriate bridging regimens prior to CARVYKTI administration. Continuous research efforts and evolving NCCN treatment guidelines contribute to improved safety profiles and therapeutic outcomes.
Bio Legend also shared preliminary data for Lucar-G39D, an investigational allogeneic CAR T-cell candidate targeting relapsed or refractory B-cell non-Hodgkin’s lymphoma. Initial results demonstrated acceptable safety parameters alongside promising antitumor responses. Diversification of the pipeline beyond CARVYKTI establishes additional growth avenues for Bio Legend stock over the medium term.
Financial Performance and Profitability Timeline
Legend Biotech posted $306 million in fourth-quarter revenue, climbing 64% year-over-year, while achieving a gross margin of 61%. Operating losses narrowed to approximately $20 million, and adjusted net income turned positive at $2.5 million versus a $59 million loss in the comparable prior-year period. Bio Legend stock benefits from management’s credible roadmap toward enterprise-wide profitability throughout 2026.
Research and development expenditures decreased 3% as BCMA frontline clinical programs advanced through later development stages, while selling, general, and administrative costs increased 22% reflecting commercial infrastructure investments. Year-end cash, cash equivalents, and time deposits stood at $949 million, with operating cash flow usage of $12 million during the quarter. Consistent sequential expansion and planned manufacturing enhancements support Bio Legend stock’s strategic positioning.
Executive leadership projects approximately 50% top-line CARVYKTI growth for 2026, propelled by international adoption acceleration and treatment site network expansion. In vivo CAR T technology development and exploration of non-viral delivery mechanisms supplement the current oncology and hematology portfolios. Collectively, Bio Legend stock performance reflects strong commercial execution, durable clinical evidence, and expanding global market penetration.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
